Summary
All extracted claims are reported as absent from the provided FDA-approved label support with no label section citations, so FDA label adherence cannot be verified.
Category Scores
Accurate Statements
Unsupported Statements
Cinacalcet is the generic name for the drug.
Marked as absent from the label with no FDA-approved label text/section citations provided.
Cinacalcet is the non-brand, international nonproprietary name (INN) for the drug.
Marked as absent from the label with no FDA-approved label text/section citations provided.
Sensipar is a brand medicine that has used the cinacalcet ingredient (depending on country/market).
Marked as absent from the label with no FDA-approved label text/section citations provided.
Mimpara is a brand medicine that has used the cinacalcet ingredient (depending on country/market).
Marked as absent from the label with no FDA-approved label text/section citations provided.
Contradictions
Important Omissions
FDA label citations/text supporting the requested naming/brand equivalence statements (generic/INN and brand names).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are about naming/brand equivalence rather than dosing or safety; however, they are unsupported by the provided FDA label evidence, making label-adherence inaccurate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All naming/brand claims lack support in the provided FDA label evidence (reported absent from label, with no cited sections).
Suggested Improvement
Replace the unsupported naming/brand statements with FDA-approved label-supported wording and include specific label section citations (e.g., wherever brand/generic naming equivalences are described in the approved labeling).